THE INGREDIENT, IN FOCUS
Thymosin Alpha-1: biology and human evidence
A peptide studied for effects on immune signaling. Immune effects depend on the illness and product. Usually a 28-amino-acid peptide, also known as thymalfasin. It is different from thymosin beta-4 or TB-500.
The biology, in plain words.
Thymosin Alpha-1 is a 28-amino-acid peptide also known as thymalfasin. It has been studied as an immune-modulating substance: one that can alter parts of an immune response. Immune activity is not a single score that should always go up. In severe illness, both weak defense and harmful inflammation can matter. This helps explain why clinical trials look at concrete outcomes, such as survival or days requiring medical support, rather than relying only on an immune marker.
The TESTS trial analyzed 1089 participants in its modified intention-to-treat population. Randomization had assigned 1106 people. The mortality difference was not clear, and the main result should take priority over exploratory subgroup patterns. Trial size alone also does not make every proposed use supported.
An immune response involves many cell types and chemical messages. More activity in one component may be helpful in one setting and unhelpful in another. That is why clinical outcomes and safety need to be measured in the relevant patient group.
What the studies found.
The 2025 TESTStrial randomized 1106 adults with sepsis. In the modified analysis,28-day mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo, with no clear difference. This does not support a general immune-boost claim or test a BPC-157 combination.
Details that change the comparison.
Thymosin alpha-1 and thymosin beta-4 have different sequences and research histories. TB-500 is often used for a beta-4-related fragment and is not an alternative name for alpha-1. The word thymosin alone does not identify which molecule a listing contains.
In the TESTS trial, survival during sepsis was the central question. Sepsis is a life-threatening illness involving the body’s response to infection. That endpoint cannot be replaced by a general immune-boost claim. A laboratory immune marker and an improvement in survival are different findings. The lack of a clear mortality difference is important even if some smaller or older studies suggested other possibilities.
Sources behind this profile.
Sources checked . Written by GotPeptide. No independent clinician review.